Physician profile
Brad Pecherzewski
NPI 1487096384
$1,540.49
in general payments reported to CMS, 2019-2025
19 companies · $16.55 in 2025
The $16.55 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $23.88 · 2023: $389 · 2024: $1,111 · 2025: $16.55.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,517.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,516.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $279.10 | 2023-2024 | Gemtesa |
| Glaxosmithkline, LLC. | $188.73 | 2024 | Arexvy, Trelegy Ellipta |
| Lilly USA, LLC | $183.85 | 2023-2024 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $146.47 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $132.52 | 2023-2024 | Airsupra, Farxiga |
| Novo Nordisk INC | $100.70 | 2023-2024 | Ozempic, Rybelsus, Wegovy |
| Otsuka America Pharmaceutical, INC. | $76.31 | 2023-2024 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $65.88 | 2023-2024 | |
| Axsome Therapeutics, INC. | $62.37 | 2023-2024 | Auvelity, Sunosi |
| Lundbeck LLC | $60.63 | 2024 | Rexulti |
| Astellas Pharma US INC | $48.80 | 2024 | Veozah |
| Pfizer INC. | $40.76 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $36.85 | 2023-2024 | Verquvo, Gardasil, Gardasil 9 |
| Mylan Specialty L.P. | $29.14 | 2023-2024 | Yupelri |
| Csl Behring | $23.88 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $19.12 | 2024 | Voquezna |
| Cipher Pharmaceuticals US LLC | $16.55 | 2025 | Spinosad, Natroba |
| Xeris Pharmaceuticals, INC. | $15.57 | 2024 | Gvoke Hypopen |
| Shield Therapeutics INC | $13.26 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brad Pecherzewski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.